Ophiuchus Technologies

Ophiuchus Technologies AG is a Swiss regenerative medicine company.

Ophiuchus Technologies AG is a Swiss regenerative medicine company founded in June 2013 as a spin-out company of the charitable NOVAGENESIS FOUNDATION, which is registered and domiciled in Switzerland. Ophiuchus Technologies is a production and distribution company for a revolutionary new cell therapy, the proprietary regenerative stem cell technology, DrSC Neural. Over a decade of top-notch research and development conducted in USA and Canada led to the inventions underlying this technology. Utilizing this disruptive technology, Ophiuchus Technologies is addressing a large population of patients that have no other effective treatment option. The product, DrSC Neural, is developed to treat patients with sub-acute and chronic spinal cord injury and traumatic brain injury, primary progressive MS (PPMS), and ALS/motor neurone disease. DrSC Neural is the first and only engineered autologous neural stem cell product for true personalised cell replacement of damaged neuronal tissue.